SCHEMBL1641016

SCHEMBL1641016

Cc1cc2[nH]c(C(=O)O)cc2c(C)c1Oc1ccc(O)c(C(=O)NC(C(C)C)C(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
THRA P10827 14/20 0.52
THRB P10828 14/20 0.52
RHEB Q15382 1/20 0.39
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6270966 0.88 THRA (0.41) THRATHRBALOX5
SCHEMBL1642020 0.84 THRB (0.68) THRATHRBRHEB
SCHEMBL1642377 0.81 THRA (0.76) THRATHRB
SCHEMBL6272512 0.79 THRB (0.45) THRATHRBRHEB
SCHEMBL1642034 0.79 THRA (0.63) THRATHRB
SCHEMBL1642280 0.78 THRA (0.49) THRATHRBRHEB
SCHEMBL6270565 0.77 THRB (0.72) THRATHRBRHEBALOX5
SCHEMBL6272069 0.76 THRB (0.47) THRATHRBRHEB
SCHEMBL1642351 0.76 THRB (0.47) THRATHRBRHEB
SCHEMBL6663984 0.74 THRA (0.66) THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds DOHERTY NIALL S 2011-04-28 US claimed
EP-1297833-B1 Indole carboxylic acids as thyroid receptor ligands PFIZER PROD INC (US) 2005-12-21 EP claimed
WO-2004047827-A1 METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2004-06-10 WO claimed
US-6723744-B2 FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA PFIZER, INC. 2004-04-20 US claimed
US-20030078289-A1 Indole carboxylic acids as thyroid receptor ligands ASPNES GARY E (US) 2003-04-24 US claimed
EP-1297833-A1 Indole carboxylic acids as thyroid receptor ligands Pfizer Products Inc. (US) 2003-04-02 EP claimed
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds DOHERTY NIALL S 2011-04-28 US disclosed
EP-1297833-B1 Indole carboxylic acids as thyroid receptor ligands PFIZER PROD INC (US) 2005-12-21 EP disclosed
WO-2004047827-A1 METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed
US-6723744-B2 FOR THERAPY OF OBESITY, OVERWEIGHT CONDITION, HYPERLIPIDEMIA, GLAUCOMA, CARDIAC ARRHYTHMIAS, SKIN DISORDER, THYROID DISEASE, HYPOTHYROIDISM, THYROID CANCER, DIABETES, ATHEROSCLEROSIS, HYPERTENSION, CORONARY HEART DISEASE, HYPERCHOLESTEREMIA PFIZER, INC. 2004-04-20 US disclosed
US-20030078289-A1 Indole carboxylic acids as thyroid receptor ligands ASPNES GARY E (US) 2003-04-24 US disclosed
EP-1297833-A1 Indole carboxylic acids as thyroid receptor ligands Pfizer Products Inc. (US) 2003-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds TPO, POLR1C, TYR THRA 21/4885THRB 29/4885RHEB 2871/4885
US-20030078289-A1 Indole carboxylic acids as thyroid receptor ligands THRA, MC1R, THRB THRA 1/4885THRB 3/4885RHEB 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.